ArticleInternational journal of hematology2006
Association of plasma adiponectin concentrations with chronic lymphocytic leukemia and myeloproliferative diseases.
Article in International journal of hematology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- Adipokines as Prognostic Biomarkers in Multiple Myeloma: A Case-Control Study.Medicina (Kaunas, Lithuania) · 2025Article
- Tumor Cell Survival Factors and Angiogenesis in Chronic Lymphocytic Leukemia: How Hot Is the Link?Cancers · 2024Review
- Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges.Current obesity reports · 2024Review
- Expression ofGastrointestinal tumors · 2020Article
- Role of bone marrow adipocytes in leukemia and chemotherapy challenges.Cellular and molecular life sciences : CMLS · 2019Review
- The prognostic value of serum and bronchoalveolar lavage levels of adiponectin in advanced non-small-cell lung cancer.Lung cancer management · 2017Article
- Adiponectin and colorectal cancer.Surgery today · 2017Review
- Evolving role of adiponectin in cancer-controversies and update.Cancer biology & medicine · 2016Article
- High Serum Adiponectin Level Is a Risk Factor for Anemia in Japanese Men: A Prospective Observational Study of 1,029 Japanese Subjects.PloS one · 2016Observational
- Adiponectin enhances Imatinib anti-tumour activity in human chronic myeloid leukaemia cells with serum levels associated with Imatinib efficacy in early chronic phase patients.Cell proliferation · 2015Article
- Expression of plasma membrane receptor genes during megakaryocyte development.Physiological genomics · 2013Article
- Role of adiponectin and its receptors in cancer.Cancer biology & medicine · 2012Article
- The role of adiponectin in cancer: a review of current evidence.Endocrine reviews · 2012Review
- Comparison of adiponectin concentration between pancreatic cancer and colorectal cancer.Journal of gastrointestinal oncology · 2011Article
- B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a case-control study in Greece.Cancer causes & control : CCC · 2010Article
- Adiponectin receptors are downregulated in human gastric cancer.Journal of gastroenterology · 2010Article
- Metabolic syndrome and cancer.Metabolic syndrome and related disorders · 2009Review
- Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia.International journal of hematology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adiponectin, an adipocyte-secreted hormone, is an important negative regulator in the immune system and hematopoiesis. In this study, we investigated the association of adiponectin levels with chronic lymphocytic leukemia (CLL) and myeloproliferative diseases (MPDs). We measured adiponectin levels in 19 patients with CLL and 30 patients with MPD (chronic myelogenous leukemia, 15; polycythemia vera, 9; myelofibrosis, 4; essential thrombocythemia, 2). The data were (chronic myelogenous leukemia, 15; polycythemia vera, 9; myelofibrosis, 4; essential thrombocythemia, 2). The data were compared with results from a control group of healthy volunteers who were matched according to age, sex, and body mass index. The adiponectin levels in patients with CLL were lower than in the controls (4.71 +/- 1.33 microg/mL versus 16.61 +/- 3.91 microg/mL; P <.001). They were also significantly lower in patients with MPD than in the controls (8.95 +/- 1.33 microg/mL versus 16.16 +/- 4.77 microg/mL; P <.001). In addition, we compared the adiponectin levels of MPD patients who were treated with interferon (IFN) to the levels of patients who were not treated with IFN. Adipnectin levels were significantly higher in IFN-treated patients (11.03 +/- 1.39 microg/mL versus 6.87 +/- 1.79 microg/mL; P <.001). These results suggest that lymphopoiesis and myelopoiesis negatively influence adiponectin levels. Adiponectin may be related to inflammatory cytokine release. IFN therapy appears to have a positive influence on adiponectin secretion by suppressing inflammatory cytokines. Future studies are needed to prove causality and to provide insight about this hormone's mechanism of action and its potential role regarding the etiology and progression of CLL and MPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.